Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Edward J Brnardic

Shawn J Stachel

Michael T Rudd

Nigel J Liverton

Mark E Fraley

Yongxin Han

Paul Tempest

Zhaoyang Meng

David Jonathan Bennett

Jiuxiang Zhu

Jenny Wai

Xuewang Xu

Bin Zhu

John M Sanders

Yuntae Kim

Melissa S Egbertson

Robert S Meissner

Cheng Wang

Robert M Garbaccio

Peter J Manley

Kenneth L Arrington

Vadim Y Dudkin

Kausik K Nanda

Vanessa L Rada

Shaei Y Huang

Kristen G Jones

Darrell Henze

Chuanman Huang

Celina V Zerbinatti

In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R, R, R, L, R, L, Q, and Rare as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use

In its many embodiments, the present invention provides certain substituted N-aryl and N-heteroaryl piperidine compounds of the Formula (I): 

N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use

In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, L, R, L, Q, and Rare as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Piperidine derivatives as liver X receptor beta agonists, compositions, and their use

In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R, R, R, R, R, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use

The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C. 

TrkA kinase inhibitors, compositions and methods thereof

The instant invention provides for compounds which comprise fused pyrazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

Inhibitors of checkpoint kinases

The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

Growing community of inventors

Lansdale, PA, United States of America

Edward J Brnardic